Diversity Supplement: Targeting chemoresistant prostate cancer with novel EED inhibitors

This Diversity Supplement will train Ms. Skylar Grayson, a highly qualified African American researcher, in cancer research and prepare her for a doctoral program in biological sciences, clinical pharmacology, or toxicology. Ms. Grayson will participate in the Specific Aims 2 and 3 as outlined in the parent grant, specifically,

evaluating the in vitro and in vivo activities of new EED inhibitors against chemoresistant PCa in preclinical models and determining the drug-like properties and toxicology of lead compounds. We will provide a candidate-specific training environment to maximize Ms. Grayson’s potential as a graduate student in

pharmacology or toxicology.